Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam for adult HAP/VAP and cIAI in China
CTR20230852Phase 4Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Apr 2023
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ceftazidime + avibactam in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), Intra-abdominal infection (IAI), sponsored by Qilu Pharmaceutical. Started Apr 2023; status: completed.
02
Drugs
ceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on CTR20230852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230852.